Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

AML

Therapeutic area intelligence for AML with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 5
Catalysts: 0
Companies: 1

Companies

Astellas Pharma Inc. →

Assets

Gilteritinib →

Recent signals(5)

ClinicalJuly 29, 2026

MyeloMATCH Trial Compares Venetoclax Combinations in Intermediate Risk AML

The MyeloMATCH trial is evaluating the efficacy of venetoclax in combination with standard therapies for younger patients with intermediate risk AML.

ClinicalJuly 27, 2026

Study on FLT3 Inhibitors' Immunological Impact Post-HSCT in AML Patients

A study is underway to evaluate the immunological effects of Gilteritinib and other FLT3 inhibitors in AML patients post-allogeneic stem cell transplantation.

ClinicalJune 30, 2026

Raloxifene identified as potential inhibitor for pediatric acute myeloid leukemia via ANP32B targeting

Raloxifene inhibits the proliferation of pediatric acute myeloid leukemia by targeting the ANP32B gene.

ClinicalJune 24, 2026

Gilteritinib vs Midostaurin Trial for FLT3 Mutated Acute Myeloid Leukemia

A clinical trial is comparing gilteritinib and midostaurin in untreated patients with FLT3 mutated AML.

ClinicalJune 17, 2026

SillaJen initiates Phase 1 trial of BAL0891 in advanced solid tumors and AML

SillaJen is conducting Phase 1 trial of BAL0891, evaluating its safety and tolerability in advanced solid tumors and relapsed/refractory AML.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.